Xilio Therapeutics Inc — Balance Sheet (NASDAQ:XLO) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Total assets 218.06 M139.16 M60.93 M71.08 M Total liabilities 32.63 M33.52 M24.1 M53.48 M Total equity 185.43 M105.65 M36.83 M17.6 M Total liabilities & shareholders' equities 218.06 M139.16 M60.93 M71.08 M Total debt ———— Net debt ————

Nachrichten

Xilio Therapeutics sichert sich 35,8 Millionen US-Dollar durch Ausübung von Optionsscheinen/n

Xilio Therapeutics secures $35.8 million from warrant exercises

Xilio Development: EPS verfehlt Schätzungen um 0,06 $ - Umsatz besser als erwartet

Xilio Development earnings missed by $0.06, revenue topped estimates

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow (NASDAQ:XLO) 2025-11-11

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Xilio presents promising data for tumor-activated immunotherapies

Xilio reports 40% response rate in colorectal cancer treatment study

Xilio to present vilastobart phase 2 data at SITC annual meeting

Xilio Therapeutics to transfer listing to Nasdaq Capital Market on Monday